HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology
07 Marzo 2024 - 2:31PM
Business Wire
Company Continues Expanding its Intellectual
Property Footprint, Now has 14 US and 4 International Patents
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company
focused on transforming cardiac care through the power of
personalized insights, announced today that it has received two new
patents on its core vectorelectrocardiography (VECG) technology
from the United States Patent and Trademark Office. HeartBeam now
has 14 issued and allowed US patents and 4 international patents
for its VECG technology which collects 3D signals of the heart and
converts them into a 12-lead ECG.
“HeartBeam’s core VECG technology is designed to be used with
portable, patient-friendly devices such as a credit-card sized
system, an extended wear patch, or watch to enable physicians to
monitor patients and identify cardiac health trends outside of a
medical facility,” said Branislav Vajdic, PhD, CEO and Founder of
HeartBeam. “These new patents reinforce our strategic vision which
is founded on developing and protecting our novel VECG technology
and product pipeline as we work to transform how cardiac care is
delivered in the future.”
The first patent, “Mobile three-lead cardiac monitoring device
and method for automated diagnostics” covers apparatuses and
methods that facilitate the comparison of cardiac signals over time
for the automated or assisted detection of heart attacks, or Acute
Myocardial Infarction (AMI). For each patient, HeartBeam provides a
comparative baseline ECG which aids physicians in gaining richer
insights about the patient’s cardiac health. This approach was
validated in a landmark JACC: Advances publication which
demonstrated that HeartBeam’s VECG approach with a comparative
baseline had significantly higher diagnostic accuracy (95% Area
Under the Curve or AUC) than a 12-lead ECG alone (68% AUC).
The second patent, “Apparatus for generating an
electrocardiogram” covers methods and apparatuses around
HeartBeam’s wrist-based ECG system. This is the second patent
related to HeartBeam’s watch concept, which combines a continuous
ECG monitor with the ability to take a high sensitivity 12-lead ECG
– all in a single device designed to be worn on the wrist.
In addition to the 14 issued and allowed US patents and 4
international patents, HeartBeam has 20 pending applications
worldwide. These patents cover the core inventions in HeartBeam’s
VECG technology, as well as the specific applications across
HeartBeam’s product portfolio, including patient carried devices
(HeartBeam AIMIGo™), continuous monitors (LIVMOR), extended wear
patches, and watch-based 12-lead ECGs.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company
that is dedicated to transforming cardiac care through the power of
personalized insights. The company’s proprietary
vectorelectrocardiography (VECG) technology collects 3D signals of
the heart’s electrical activity and converts them into a 12-lead
ECG. This platform technology is designed to be used on portable,
patient-friendly devices such as a credit-card sized monitor, watch
or patch. Physicians will be able to identify cardiac health trends
and acute conditions and direct patients to the appropriate care –
all outside of a medical facility, thus redefining how cardiac
health is managed in the future. For additional information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our Forms 10-K, 10-Q and other reports filed with the SEC and
available at www.sec.gov. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240307488461/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact:media@heartbeam.com
Grafico Azioni HeartBeam (NASDAQ:BEAT)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni HeartBeam (NASDAQ:BEAT)
Storico
Da Dic 2023 a Dic 2024